Inhaled Levodopa (CVT-301) Offers Non-Invasive Therapy for Parkinson’s Disease

EMBARGOED until Monday, June 15, 2015
Media Contact:

Elizabeth Clausen, +1 414-276-2145, eclausen@movementdisorders.org
 

Inhaled Levodopa (CVT-301) Offers Non-Invasive Therapy for Parkinson’s Disease


SAN DIEGO – Inhaled levodopa (CVT-301) provides rapid motor improvement in Parkinson’s disease (PD), according to a study released today at the 19th International Congress of Parkinson’s Disease and Movement Disorders.

Levodopa is already known as the most effective treatment for PD motor symptoms, and irregular absorption diminishes levodopa as a reliable therapy method to improve PD patients experiencing OFF states. CVT-301 has been developed to treat OFF episodes and following inhalation, concentrations rise rapidly within approximately ten minutes to therapeutic levels. Eighty-six patients were randomized with either CVT-301 or placebo, and onset of action was based on UPDRS III score improvements. With an average daily use of approximately two times per day, CVT-301was associated with a 1.6 hour reduction in daily OFF time, or a 30-35% reduction from baseline during the period of use. In addition, no increase in ON time with dyskinesia was evident.

Peter Jenner, Professor of Pharmacology and Therapeutics at King’s College London states, “This work is important as it appears to offer a further and novel route of administration of levodopa that can be used to treat OFF periods. My immediate thought is that it will offer an alternative to rescue from ‘off’ periods currently achieved by subcutaneous injection of apomorphine. A non-invasive form of rescue therapy will have utility and convenience for patients with Parkinson’s disease experiencing sudden ‘off’ and improve their quality of life.”

About the 19th International Congress of Parkinson's Disease and Movement Disorders:
Meeting attendees are gathered to learn the latest research findings and state-of-the-art treatment options in Movement Disorders, including Parkinson's disease. Over 3,500 physicians and medical professionals from more than 80 countries will be able to view over 1,500 scientific abstracts submitted by clinicians from around the world.

About the International Parkinson and Movement Disorder Society:
The International Parkinson and Movement Disorder Society (MDS), an international society of over 5,000 clinicians, scientists, and other healthcare professionals, is dedicated to improving patient care through education and research. For more information about MDS, visit www.movementdisorders.org.

Top